Related Experiment Video

Updated: Jul 10, 2026

Retinal Pigment Epithelium Transplantation in a Non-human Primate Model for Degenerative Retinal Diseases
11:20

Retinal Pigment Epithelium Transplantation in a Non-human Primate Model for Degenerative Retinal Diseases

Published on: June 14, 2021

siRNA targeting mammalian target of rapamycin (mTOR) attenuates experimental proliferative vitreoretinopathy

Peng Zhou1, Ming-Wei Zhao, Xiao-Xin Li

  • 1Department of Ophthalmology, Peking University People's Hospital, Beijing, China.

Current Eye Research
|November 21, 2007
PubMed
Abstract

Insights

Gene therapy using mammalian target of rapamycin (mTOR) specific small interfering RNA (siRNA) significantly reduced proliferative vitreoretinopathy (PVR) in a rabbit model. This approach shows promise for preventing PVR in humans.

Area of Science:

  • Ophthalmology
  • Molecular Biology
  • Gene Therapy

Background:

  • Proliferative vitreoretinopathy (PVR) is a severe complication following retinal detachment surgery.
  • The mammalian target of rapamycin (mTOR) pathway plays a critical role in cellular processes implicated in PVR pathogenesis.

Purpose of the Study:

  • To evaluate the therapeutic potential of mTOR-specific small interfering RNA (siRNA) in mitigating PVR.
  • To investigate the effect of inhibiting mTOR on key cellular behaviors contributing to PVR.

Main Methods:

  • Human retinal pigment epithelial (hRPE) cells (D407) were treated with mTOR-specific siRNA.
  • Assays assessed cell proliferation, attachment, spreading, and migration.
  • A rabbit model of PVR was established and treated with mTOR-specific siRNA to assess its in vivo efficacy.

Main Results:

  • mTOR inhibition via siRNA reduced hRPE cell spreading and migration by approximately 82%.
  • In the rabbit PVR model, mTOR-specific siRNA significantly decreased the incidence and severity of retinal detachment, observed in 50% of treated animals compared to 100% in controls.

Conclusions:

  • Gene therapy targeting mTOR with siRNA effectively attenuates PVR in a preclinical animal model.
  • mTOR-specific siRNA represents a potential novel therapeutic strategy for the prevention and treatment of human PVR.

More Related Videos

Mechanistic Insight into the Development of TNBS-Mediated Intestinal Fibrosis and Evaluating the Inhibitory Effects of Rapamycin10:21

Mechanistic Insight into the Development of TNBS-Mediated Intestinal Fibrosis and Evaluating the Inhibitory Effects of Rapamycin

Published on: September 12, 2019

Assessment of Vascular Regeneration in the CNS Using the Mouse Retina07:32

Assessment of Vascular Regeneration in the CNS Using the Mouse Retina

Published on: June 23, 2014

Related Concept Videos

mTOR Signaling and Cancer Progression03:03

mTOR Signaling and Cancer Progression

The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
mTOR Signaling and Cancer Progression03:03

mTOR Signaling and Cancer Progression

The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
PI3K/mTOR/AKT Signaling Pathway01:22

PI3K/mTOR/AKT Signaling Pathway

The mammalian target of rapamycin  (mTOR) is a serine/threonine kinase that regulates growth, proliferation, and cell survival in response to hormones, growth factors, or nutrient availability. This kinase exists in two structurally and functionally distinct forms: mTOR complex 1  (mTORC1) and mTOR complex 2  (mTORC2). The first form (mTORC1) is composed of a rapamycin-sensitive Raptor and proline-rich Akt substrate, PRAS40. In contrast,  mTORC2 consists of a rapamycin-insensitive companion...